실시간
FierceBiotechPredicta links with Spanish university to offer diagnostic for blood cancersBioPharma DiveSummit pulls $500M share sale a day after announcing itEndpoints NewsDrugmakers are turning to logistics providers as trade disruptions linger, DHL exec saysBioPharma DiveSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapyEndpoints NewsSummit withdraws $500M offering, citing 'market conditions'BioWorldScore in phase I CML trial has Enliven looking ahead to phase IIIClinical OMICsLipid-Protein Biomarker Makes Clinical Debut with Early Ovarian Cancer DetectionEndpoints NewsSensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyEndpoints NewsCamurus’ second CRL for acromegaly drug; Teva details workforce cutsFierceBiotechFierce Biotech heading to UK to host event amid London Life Sciences WeekBioPharma DiveNovartis RNA drug acquired in $12B Avidity deal notches a trial winEndpoints NewsBiopharma pay report: Top-paid CSOs, CMOs of 2025
BioWorld 2025년 11월 25일

Protara sees Chugai blue sky in LMs as phase II data strong

Protara sees Chugai blue sky in LMs as phase II data strong

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.